|
|
Discussion on the characteristics of traditional Chinese medicine pathogenesis of early liver cirrhosis of chronic hepatitis B |
ZHAI Changming1 LU Fang1 GAO Ya2 |
1.College of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China;
2.China Institute for History of Medicine and Medical Literature, China Academy of Chinese Medical Sciences, Beijing 100700, China |
|
|
Abstract Hepatitis B virus (HBV) infection is the most common cause of liver cirrhosis in China. However, due to the long-term and occult progression of liver cirrhosis, the diagnosis and treatment of early liver cirrhosis is still a world problem to be solved. From the perspective of traditional Chinese medicine, HBV should be the evil of dampness and heat, the deficiency of vital qi in the body is an important cause of chronic HBV infection, and phlegm turbidity and blood stasis are the pathological basis of liver fibrosis/cirrhosis, and “fire, dampness, deficiency, phlegm and blood stasis” are the core pathogenesis of early liver cirrhosis. Compared with modern medicine, traditional Chinese medicine has its unique advantages. It can apply decoction based on syndrome differentiation according to the pathogenesis, and intervene in advance through non-drug means such as acupuncture, massage and guidance, so as to jointly play the role of “prevention before disease and treatment before disease”.
|
|
|
|
|
[1] Cao X,Shang QH,Chi XL,et al. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus [J]. World J Gastroenterol,2020,26(10):1067-1079.
[2] Arvaniti V,D’Amico G,Fede G,et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis [J]. Gastroenterology,2010,139(4):1246-1256.
[3] 徐小元,丁惠国,李文刚,等.肝硬化诊治指南[J].临床肝胆病杂志,2019,35(11):2408-2425.
[4] Liu J,Zhang S,Wang Q,et al. Seroepidemiology of hepatitis B virus infection in 2 million men aged 21-49 years in rural China:a population-based,cross-sectional study [J]. Lancet Infect Dis,2016,16(1):80-86.
[5] 童光东,王宇新,邢宇锋,等.从“虚、毒、瘀、积”论慢性乙型肝炎及相关肝硬化、肝癌的治疗[J].中医杂志,2021, 62(16):1404-1407.
[6] 张佳.基于真实世界的慢性乙型肝炎中西医结合治疗的回顾性队列研究[D].武汉:湖北中医药大学,2021.
[7] 王贵强,段钟平,王福生,等.慢性乙型肝炎防治指南(2019年版)[J].实用肝脏病杂志,2020,23(1):后插9-后插32.
[8] 翟昌明,鲁放,马重阳,等.试述肝火证、炎症反应、高血压三者之关系[J].环球中医药,2019,12(12):1858-1861.
[9] 王春芳,刘光伟,陈建杰.从湿邪论治慢性乙型肝炎探讨[J].世界中医药,2007,2(2):99-100.
[10] 杨军,屈杰,陈丽名.国医大师周信有论治慢性乙型病毒性肝炎学术思想和临证经验[J].中国中医药信息杂志,2021,28(8):118-120.
[11] Meng ZJ,Chen YY,Lu MJ. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection [J]. Front Immunol,2020,10:3127.
[12] 陈刚.试论中医理论中的免疫学思想[J].吉林中医药,2006,24(4):1-3.
[13] 董振华.中医有关免疫学思想的探讨[J].山西中医,1986(1):40-42.
[14] 王俐钧,孙建光.从邪正关系探讨HBV感染的自然史机制[J].四川中医,2019,37(2):30-32.
[15] 徐列明,刘平,沈锡中,等.肝纤维化中西医结合诊疗指南(2019年版)[J].中国中西医结合杂志,2019,39(11):1286-1295.
[16] Yin Y,Kong D,He K,et al. Regeneration and activation of liver progenitor cells in liver cirrhosis [J]. Genes Dis,2021,8:623-628.
[17] Bedossa P. Reversibility of hepatitis B virus cirrhosis after therapy:who and why? [J]. Liver Int,2015,35 Suppl 1:78-81.
[18] 陈帅,杨长青.门静脉血栓病因及危险因素研究进展[J].实用肝脏病杂志,2019,22(6):761-764.
[19] 廖宇,宋翊.从痰瘀阻络论治肝纤维化肝硬化[J].四川中医,2016,34(1):38-40.
[20] 赵志敏,李正鑫,朱亭亭,等.中医药改善乙型肝炎肝硬化血管重塑研究思路[J].中医杂志,2020,61(15):1318-1321.
[21] 杨爱婷,严旭禛,赵文姗,等.肝纤维化小鼠模型中弹性蛋白及其调控因子在肝纤维化形成和逆转中的分子机制[J].临床肝胆病杂志,2020,36(7):1514-1519.
[22] 周文泉,方凡.抓主证,求主因,标本缓急须分清——疑难重症诊疗思路琐谈[J].天津中医,1992(5):44,14.
[23] 苗亮,杨婉娜,董晓琴,等.安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J].中华肝脏病杂志,2019,27(7):521-526.
[24] 戈雪婧,赵长青,徐列明.扶正化瘀胶囊对肝硬化患者生存率的影响[J].中华肝脏病杂志,2017,25(11):834-840.
[25] 张志斌,王永炎.试论中医“治未病”之概念及其科学内容[J].北京中医药大学学报,2007,30(7):440-444.
[26] 叶永安.慢性乙型肝炎的治疗现状与中医药“免疫孵育”策略的实践[J].中西医结合肝病杂志,2021,31(2):97-101.
[27] 李昊原,张林.叶天士湿秽致病说及治法用方浅谈[J].中医学报,2020,35(11):2298-2301.
[28] 訾璐,徐艺,王玉,等.利水软肝汤、中药敷脐联合温针灸对肝硬化腹水患者肝功能、尿量和门静脉血流动力学的影响[J].中西医结合肝病杂志,2021,31(1):40-43.
[29] 张莹雪,孙凤霞,李晓玲,等.基于CiteSpace的中医药治疗肝硬化热点与前沿分析[J].中国医药导报,2022,19(14):14-18.
[30] 蒋鑫,姜莹,李秀云.椒目泄水贴穴位外敷联合西药治疗肝硬化腹水30例临床观察[J].湖南中医杂志,2021, 37(9):74-77.
[31] 刘巍,熊兴江,王阶.高血压前期的中医认识及治疗[J].中国中药杂志,2013,38(14):2416-2420. |
|
|
|